ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
1.65
-0.09 (-5.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.74
Open1.77
Bid0.00 x 900
Ask0.00 x 1100
Day's Range1.63 - 1.79
52 Week Range1.36 - 2.98
Volume6,228
Avg. Volume28,298
Market Cap147.136M
Beta (3Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire5 hours ago

    Zomedica Pharmaceuticals Corp. Announces Third Quarter 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2018. Zomedica recorded net loss and comprehensive loss for the three and nine months ended September 30, 2018 of $1,910,278 or $0.02 per share and $8,226,005 or $0.09 per share, compared to a loss of $2,080,682 or $0.02 per share and $5,501,788 or $0.06 per share for the three and nine months ended September 30, 2017. Zomedica, which is in the development stage, recorded no revenues in the three and nine months ended September 30, 2018.

  • GlobeNewswireyesterday

    Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI

    ANN ARBOR, Mich., Nov. 12, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • ACCESSWIRE29 days ago

    SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp.

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (ZOM). The report is available here: ZOM Update Note. Based in Ann Arbor, MI, Zomedica Pharmaceuticals Corp. (NYSE American: ZOM, TSXV: ZOM, "Zomedica") is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine).

  • GlobeNewswire2 months ago

    Zomedica Pharmaceuticals Corp. to Present at LD Micro NYC Summit and Cantor 2018 Global Healthcare Conference

    ANN ARBOR, Mich., Sept. 18, 2018-- Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, today announced that it will present at the LD Micro NYC Summit on September 25 in ...

  • ACCESSWIRE6 months ago

    Wired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for Veterinarians

    LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on Zomedica Pharma Corp. (NYSE: ZOM) ("Zomedica"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZOM as the Company's latest news hit the wire. On May 10, 2018, the Company announced that it has inked a deal with Seraph Biosciences, Inc. ("Seraph"), which is a human biomedical device organization, thereby securing exclusive global veterinary industry rights to develop and market Seraph's novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument. Active-Investors.com is currently working on the research report for Catalent, Inc. (NYSE: CTLT), which also belongs to the Healthcare sector as the Company Zomedica Pharma.

  • ACCESSWIRE8 months ago

    SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)

    NEW YORK, NY / ACCESSWIRE / March 26, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

  • ACCESSWIRE11 months ago

    SeeThruEquity Initiates Coverage on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) with a Price Target of $3.24

    Initiating Coverage with a Price Target of US $3.24 NEW YORK, NY / ACCESSWIRE / December 1, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and ...